Francisco Leon
Founder chez PROVENTION BIO, INC.
Profil
Francisco Leon is the founder of Provention Bio, Inc. (founded in 2016) and Glutenostics LLC (founded in 2016).
He is also the founder of Celimmune LLC (founded in 2015).
Currently, Dr. Leon is the Director at Vaxdyn SL and the Associate Professor at Sidney Kimmel Medical College.
In his former positions, he worked as the Director-Clinical Discovery, Immunology & Oncology at Bristol Myers Squibb Co., Director-Clinical Development at MedImmune LLC, Associate Professor at Thomas Jefferson University, VP & Head-Translational Medicine at Janssen Pharmaceuticals, Inc., and Chief Medical Officer & Vice President at Alba Therapeutics Corp.
(from 2007 to 2010).
Dr. Leon obtained a doctorate degree from Universidad Autónoma de Madrid.
Postes actifs de Francisco Leon
Sociétés | Poste | Début |
---|---|---|
PROVENTION BIO, INC. | Founder | 04/10/2016 |
Sidney Kimmel Medical College | Corporate Officer/Principal | 01/01/2011 |
Glutenostics LLC
Glutenostics LLC Electronic Equipment/InstrumentsElectronic Technology Glutenostics LLC engages in the manufacture of urine and stool test products and retail through online. The company was founded by Angel Cebolla Ramirez and Francisco Leon in 2016 and is headquartered in Los Angeles, CA. | Founder | 01/01/2016 |
Vaxdyn SL
Vaxdyn SL BiotechnologyHealth Technology Vaxdyn SL discovers and develops antigens. Its products include pipeline, clinical need and R&D programs. The company was founded by Jeronimo Pachon, Pilar Perez-Romero and Michael J. McConnell in 2011 and is headquartered in Seville, Spain. | Director/Board Member | - |
Anciens postes connus de Francisco Leon
Sociétés | Poste | Fin |
---|---|---|
Alba Therapeutics Corp.
Alba Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies | Chief Tech/Sci/R&D Officer | 01/09/2010 |
Thomas Jefferson University | Corporate Officer/Principal | - |
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Private Equity Analyst | - |
Celimmune LLC
Celimmune LLC Hospital/Nursing ManagementHealth Services Celimmune LLC is an American company that is not described in the provided metadata. Therefore, no summary can be provided. | Chief Executive Officer | - |
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Formation de Francisco Leon
Universidad Autónoma de Madrid | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
Entreprise privées | 7 |
---|---|
MedImmune LLC
MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Health Technology |
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Health Technology |
Alba Therapeutics Corp.
Alba Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies | Health Technology |
Vaxdyn SL
Vaxdyn SL BiotechnologyHealth Technology Vaxdyn SL discovers and develops antigens. Its products include pipeline, clinical need and R&D programs. The company was founded by Jeronimo Pachon, Pilar Perez-Romero and Michael J. McConnell in 2011 and is headquartered in Seville, Spain. | Health Technology |
Provention Bio, Inc.
Provention Bio, Inc. Pharmaceuticals: MajorHealth Technology Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ. | Health Technology |
Glutenostics LLC
Glutenostics LLC Electronic Equipment/InstrumentsElectronic Technology Glutenostics LLC engages in the manufacture of urine and stool test products and retail through online. The company was founded by Angel Cebolla Ramirez and Francisco Leon in 2016 and is headquartered in Los Angeles, CA. | Electronic Technology |
Celimmune LLC
Celimmune LLC Hospital/Nursing ManagementHealth Services Celimmune LLC is an American company that is not described in the provided metadata. Therefore, no summary can be provided. | Health Services |